Download PDF
Aktuelle Neurologie 2005; 32: 40-44
DOI: 10.1055/s-2004-834697
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Subkutane Applikation von Apomorphin - Pharmakologische Eigenschaften und alternative Applikationswege

Subcutaneous Application of Apomorphin - Pharmacological Properties and Alternative FormulationsJ.  P.  Sieb1 , A.  Storch2
  • 1Klinik für Neurologie, Geriatrie und Palliativmedizin, Hanse-Klinikum Stralsund
  • 2Klinik und Poliklinik für Neurologie (Direktor: Prof. Dr. Heinz Reichmann), Technische Universität Dresden
Further Information

Publication History

Publication Date:
26 April 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Apomorphin ist ein Non-Ergot-Aporphinalkaloid vom Dibenzochinolintyp und wirkt als potenter Dopaminagonist. Der schnelle hepatische Metabolismus („First-pass-Effekt”) von Apomorphin macht die orale Applikation unmöglich, sodass die subkutane Injektion in der Therapie des Morbus Parkinson favorisiert wird. Weiterhin sind auch die intranasale, sublinguale, rektale und intravenöse Gabe in der Behandlung des Morbus Parkinson getestet worden. Bei subkutaner Applikation ist die maximale Plasmakonzentration im Mittel nach 10 - 20 Minuten erreicht (Tmax), die klinische Wirkung tritt zwischen 7 - 17 Minuten ein. Apomorphin wird im Wesentlichen über nicht enzymatische Oxidation abgebaut, daneben findet die N-Methylierung, Sulfatierung, Glukuronidierung und Catechol-O-Methylierung von Apomorphin statt. In dieser Übersicht werden die pharmakologischen Eigenschaften von subkutan injiziertem Apomorphin detailliert geschildert und die alternativen Applikationswege diskutiert.

Abstract

Apomorphine is a non-ergot aporphine alkaloid with a dibenzoquinoline structure and acts as a potent dopamine agonist. The high hepatic first-pass metabolism of apomorphine prevents its use by the oral route, but the subcutaneous injection is the usual route in the treatment of Parkinson's disease. Furthermore, the intranasal, sublingual, rectal and intravenous application has been investigated in Parkinson's disease. After subcutaneous application the maximal plasma concentration occurs after 10 to 20 minutes (Tmax), and the clinical effects start after 7 to 17 minutes. Apomorphin is metabolized mainly by non-enzymatic oxidation, but enzymatic pathways including N-methylation, sulfation, glucuronidation, and catechol-O-methylation are also detected. In the present review we summarize the pharmacological properties of subcutaneously administered apomorphin and discuss the alternative application routes.

Literatur

  • 1 Neumeyer J L, Lal S, Baldessarini R J. Historical highlights of the chemistry, pharmacology, and early clinical use of apomorphine. In: Gessa GL, Corsini GU (eds) Apomorphine and Other Dopaminomimetics. New York; Raven Press 1981
    Google Scholar
  • 2 Argiolas A, Hedlund H. The pharmacology and clinical pharmacokinetics of apomorphine SL.  BJU Int. 2001;  88, Suppl 3 18-21
    CrossrefPubMedGoogle Scholar
  • 3 Schwab R S, Amador L V, Lettvin J Y. Apomorphine in Parkinson's disease.  Trans Am Neurol Assoc. 1951;  56 251-253
    PubMedGoogle Scholar
  • 4 Corsini G U, Zompo M Del, Gessa G L, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.  Lancet. 1979;  1 954-956
    PubMedGoogle Scholar
  • 5 Cotzias G C, Papavasiliou P S, Fehling C. et al . Similarities between neurologic effects of L-dopa and of apomorphine.  N Engl J Med. 1970;  282 31-33
    PubMedGoogle Scholar
  • 6 Stibe C M, Lees A J, Kempster P A, Stern G M. Subcutaneous apomorphine in parkinsonian on-off oscillations.  Lancet. 1988;  1 403-406
    PubMedGoogle Scholar
  • 7 Dewey Jr R B, Hutton J T, LeWitt P A, Factor S A. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.  Arch Neurol. 2001;  58 1385-1392
    CrossrefPubMedGoogle Scholar
  • 8 Pollak P, Champay A S, Hommel M. et al . Subcutaneous apomorphine in Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1989;  52 544
    PubMedGoogle Scholar
  • 9 Colosimo C, Merello M, Albanese A. Clinical usefulness of apomorphine in movement disorders.  Clin Neuropharmacol. 1994;  17 243-259
    PubMedGoogle Scholar
  • 10 Colzi A, Turner K, Lees A J. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1998;  64 573-576
    CrossrefPubMedGoogle Scholar
  • 11 Frankel J P, Lees A J, Kempster P A, Stern G M. Subcutaneous apomorphine in the treatment of Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1990;  53 96-101
    CrossrefPubMedGoogle Scholar
  • 12 Kanovsky P, Kubova D, Bares M. et al . Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.  Mov Disord. 2002;  17 188-191
    CrossrefPubMedGoogle Scholar
  • 13 Poewe W, Kleedorfer B, Wagner M. et al . Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.  Adv Neurol. 1993;  60 656-659
    PubMedGoogle Scholar
  • 14 Goldman M E, Kebabian J W. Apomorphine enantiomers. Interactions with D1 and D2 dopamine receptors.  Mol Pharmacol. 1984;  25 18-23
    PubMedGoogle Scholar
  • 15 Burkman A M. Some kinetic and thermodynamic characteristics of apomorphine degradation.  J Pharm Sci. 1965;  54 325-331
    CrossrefPubMedGoogle Scholar
  • 16 Youdim M B, Gassen M, Gross A. et al . Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine.  J Neural Transm Suppl. 2000;  58 83-96
    PubMedGoogle Scholar
  • 17 Sam E E, Verbeke N. Free radical scavenging properties of apomorphine enantiomers and dopamine: possible implication in their mechanism of action in parkinsonism.  J Neural Transm Park Dis Dement Sect. 1995;  10 115-127
    PubMedGoogle Scholar
  • 18 Gassen M, Glinka Y, Pinchasi B, Youdim M B. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction.  Eur J Pharmacol. 1996;  308 219-225
    CrossrefPubMedGoogle Scholar
  • 19 Gassen M, Gross A, Youdim M B. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine.  Mov Disord. 1998;  13 661-667
    CrossrefPubMedGoogle Scholar
  • 20 Grunblatt E, Mandel S, Berkuzki T, Youdim M B. Apomorphine protects against MPTP-induced neurotoxicity in mice.  Mov Disord. 1999;  14 612-618
    CrossrefPubMedGoogle Scholar
  • 21 Grunblatt E, Mandel S, Gassen M, Youdim M B. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity.  J Neural Transm Suppl. 1999;  55 57-70
    PubMedGoogle Scholar
  • 22 Fornai F, Battaglia G, Gesi M. et al . Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage.  Brain Res. 2001;  898 27-35
    CrossrefPubMedGoogle Scholar
  • 23 Hara H, Ohta M, Ohta K. et al . Apomorphine attenuates 6-hydroxydopamine-induced apoptotic cell death in SH-SY5Y cells.  Redox Rep. 2003;  8 193-197
    CrossrefPubMedGoogle Scholar
  • 24 Kyriazis M. Neuroprotective, anti-apoptotic effects of apomorphine.  J Anti Aging Med. 2003;  6 21-28
    CrossrefPubMedGoogle Scholar
  • 25 Newman-Tancredi A, Cussac D, Quentric Y. et al . Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.  J Pharmacol Exp Ther. 2002;  303 815-822
    CrossrefPubMedGoogle Scholar
  • 26 Newman-Tancredi A, Cussac D, Audinot V. et al . Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.  J Pharmacol Exp Ther. 2002;  303 805-814
    CrossrefPubMedGoogle Scholar
  • 27 Hutchinson W D, Levy R, Dostrovsky J O. et al . Effects of apomorphine on globus pallidus neurons in parkinsonian patients.  Ann Neurol. 1997;  42 767-775
    CrossrefPubMedGoogle Scholar
  • 28 Millan M J, Maiofiss L, Cussac D. et al . Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.  J Pharmacol Exp Ther. 2002;  303 791-804
    CrossrefPubMedGoogle Scholar
  • 29 Mulhall J P. Sublingual apomorphine for the treatment of erectile dysfunction.  Expert Opin Investig Drugs. 2002;  11 295-302
    CrossrefPubMedGoogle Scholar
  • 30 Dula E, Bukofzer S, Perdok R, George M. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction.  Eur Urol. 2001;  39 558-563; discussion 564
    CrossrefPubMedGoogle Scholar
  • 31 Eardley I, Wright P, MacDonagh R. et al . An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction.  BJU Int. 2004;  93 1271-1275
    CrossrefPubMedGoogle Scholar
  • 32 Colpaert F C, Bever W F Van, Leysen J E. Apomorphine: chemistry, pharmacology, biochemistry.  Int Rev Neurobiol. 1976;  19 225-268
    PubMedGoogle Scholar
  • 33 Chiara G Di, Gessa G L. Pharmacology and neurochemistry of apomorphine.  Adv Pharmacol Chemother. 1978;  15 87-160
    PubMedGoogle Scholar
  • 34 Cotzias G C, Papavasiliou P S, Tolosa E S. et al . Treatment of Parkinson's disease with apomorphines. Possible role of growth hormone.  N Engl J Med. 1976;  294 567-569
    PubMedGoogle Scholar
  • 35 Gancher S T, Woodward W R, Boucher B, Nutt J G. Peripheral pharmacokinetics of apomorphine in humans.  Ann Neurol. 1989;  26 232-238
    CrossrefPubMedGoogle Scholar
  • 36 Nicolle E, Pollak P, Serre-Debeauvais F. et al . Pharmacokinetics of apomorphine in parkinsonian patients.  Fundam Clin Pharmacol. 1993;  7 245-252
    CrossrefPubMedGoogle Scholar
  • 37 Sam E, Jeanjean A P, Maloteaux J M, Verbeke N. Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application.  Eur J Drug Metab Pharmacokinet. 1995;  20 27-33
    CrossrefPubMedGoogle Scholar
  • 38 Harder S, Baas H, Demisch L, Simon E. Dose response and concentration response relationship of apomorphine in patients with Parkinson's disease and end-of-dose akinesia.  Int J Clin Pharmacol Ther. 1998;  36 355-362
    PubMedGoogle Scholar
  • 39 Ostergaard L, Werdelin L, Odin P. et al . Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.  J Neurol Neurosurg Psychiatry. 1995;  58 681-687
    CrossrefPubMedGoogle Scholar
  • 40 Laar T van, Neef C, Danhof M. et al . A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease.  Mov Disord. 1996;  11 633-638
    CrossrefPubMedGoogle Scholar
  • 41 Hofstee D J, Neef C, Laar T van, Jansen E N. Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses.  Clin Neuropharmacol. 1994;  17 45-52
    PubMedGoogle Scholar
  • 42 Przedborski S, Levivier M, Raftopoulos C. et al . Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans.  Mov Disord. 1995;  10 28-36
    CrossrefPubMedGoogle Scholar
  • 43 Gervason C L, Pollak P R, Limousin P, Perret J E. Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease.  Clin Neuropharmacol. 1993;  16 113-119
    CrossrefPubMedGoogle Scholar
  • 44 Laar T van, Jansen E N, Essink A W. et al . A double-blind study of the efficacy of apomorphine and its assessment in „off”-periods in Parkinson's disease.  Clin Neurol Neurosurg. 1993;  95 231-235
    CrossrefPubMedGoogle Scholar
  • 45 Deffond D, Durif F, Tournilhac M. Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.  J Neurol Neurosurg Psychiatry. 1993;  56 101-103
    PubMedGoogle Scholar
  • 46 Verhagen Metman L, Locatelli E R, Bravi D. et al . Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.  Neurology. 1997;  48 369-372
    PubMedGoogle Scholar
  • 47 Kapoor R, Turjanski N, Frankel J. et al . Intranasal apomorphine: a new treatment in Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1990;  53 1015
    PubMedGoogle Scholar
  • 48 Kleedorfer B, Turjanski N, Ryan R. et al . Intranasal apomorphine in Parkinson's disease.  Neurology. 1991;  41 761-762
    PubMedGoogle Scholar
  • 49 Laar T van, Jansen E N, Essink A W, Neef C. Intranasal apomorphine in parkinsonian on-off fluctuations.  Arch Neurol. 1992;  49 482-484
    PubMedGoogle Scholar
  • 50 Hughes A J, Webster R, Bovingdon M. et al . Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations.  Clin Neuropharmacol. 1991;  14 556-561
    PubMedGoogle Scholar
  • 51 Montastruc J L, Rascol O, Senard J M. et al . Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.  Clin Neuropharmacol. 1991;  14 432-437
    PubMedGoogle Scholar
  • 52 Hughes A J, Bishop S, Lees A J. et al . Rectal apomorphine in Parkinson's disease.  Lancet. 1991;  337 118
    PubMedGoogle Scholar
  • 53 Bodde H E, Laar T van, Geest R Van der, Danhof M. An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease.  Adv Drug Deliv Rev. 1998;  33 253-263
    CrossrefPubMedGoogle Scholar
  • 54 Junginger H E. Iontophoretic delivery of apomorphine: from in-vitro modelling to the Parkinson patient.  Adv Drug Deliv Rev. 2002;  54, Suppl 1 S57-75
    CrossrefPubMedGoogle Scholar
  • 55 Gancher S T, Nutt J G, Woodward W R. Absorption of apomorphine by various routes in parkinsonism.  Mov Disord. 1991;  6 212-216
    CrossrefPubMedGoogle Scholar
  • 56 Gancher S T, Nutt J G, Woodward W R. Time course of tolerance to apomorphine in parkinsonism.  Clin Pharmacol Ther. 1992;  52 504-510
    PubMedGoogle Scholar
  • 57 Ugwoke M I, Agu R U, Kinget R, Verbeke N. Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox.  Boll Chim Farm. 2003;  142 315-327
    PubMedGoogle Scholar
  • 58 Geest R van der, Laar T van, Kruger P P. et al . Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease.  Clin Neuropharmacol. 1998;  21 159-168
    PubMedGoogle Scholar
  • 59 Thomas N L, Coughtrie M W. Sulfation of apomorphine by human sulfotransferases: evidence of a major role for the polymorphic phenol sulfotransferase, SULT1A1.  Xenobiotica. 2003;  33 1139-1148
    CrossrefPubMedGoogle Scholar
  • 60 Neef C, Laar T van. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.  Clin Pharmacokinet. 1999;  37 257-271
    PubMedGoogle Scholar
  • 61 LeWitt P A. Subcutaneously administered apomorphine: pharmacokinetics and metabolism.  Neurology. 2004;  62 (6 Suppl 4) S8-11
    CrossrefPubMedGoogle Scholar
  • 62 Picada J N, Maris A F, Ckless K. et al . Differential mutagenic, antimutagenic and cytotoxic responses induced by apomorphine and its oxidation product, 8-oxo-apomorphine-semiquinone, in bacteria and yeast.  Mutat Res. 2003;  539 29-41
    PubMedGoogle Scholar

Prof. Dr. Jörn P. Sieb

Chefarzt der Klinik für Neurologie, Geriatrie und Palliativmedizin · Hanse-Klinikum

Große Parower Straße 47 - 53

18410 Stralsund

Email: j.sieb@klinikum-hst.de